Shots:

• The P-III IMpower010 involves assessing Tecentriq + BSC in 1-005 participants in a ratio (1:1) with Stage IB-IIIA NSCLC- following surgical resection and up to 4 cycles of adjuvant cisplatin-based CT
• Results: 34% reduction in risk of death in people with Stage II-IIIA NSCLC. In the larger population of all randomized Stage II-IIIA study patients showed a 21% reduction in risk of disease recurrence or death after a median follow-up of 32.2mos- DFS (42.3mos. vs 35.3mos.)- no new safety signals were observed
• Tecentriq is the first and only cancer immunotherapy to show positive P-III results in the adjuvant lung cancer setting

  Ref: Businesswire | Image: Center for Health Journalism